Matricelf
Matricelf is a biotechnology company developing personalized autologous engineered neural tissue implants for spinal cord injury. Its approach combines patient-derived cells with biomaterials. The company is conducting preclinical studies and preparing manufacturing and regulatory activities toward human clinical development.
Industries
Nr. of Employees
small (1-50)
Products
An investigational engineered neural tissue implant made using patient-derived cells and biomaterials, being developed for spinal cord injury. It has not yet been evaluated in humans.
An investigational engineered neural tissue implant made using patient-derived cells and biomaterials, being developed for spinal cord injury. It has not yet been evaluated in humans.
Expertise Areas
- Regenerative medicine
- Spinal cord injury
- Neural tissue engineering
- Autologous cell-based therapies
Key Technologies
- Induced pluripotent stem cells
- Neural tissue engineering
- Decellularized omentum-derived biomaterials
- Hydrogel scaffolds
Key People
Chief Executive Officer
Vice President of Research and Development
prof. Tal Dvir
Co-Founder & CSO
Alon Sinai
Co-Founder, Deputy CEO & President
Chief Executive Officer
Vice President of Research and Development
prof. Tal Dvir
Co-Founder & CSO
Alon Sinai
Co-Founder, Deputy CEO & President
News & Updates
The company was selected for the award at Advanced Therapies Week, according to the announcement.
The company reported FDA feedback supporting key elements of its proposed trial, including the patient population, open-label single-arm design, and safety assessments. The feedback was based on a limited trial synopsis and is not clearance of an IND or authorization to begin a trial.
The company reported approval to collect blood samples from patients with complete spinal cord injuries for induced pluripotent stem cell generation. The approval does not authorize implantation or initiation of a clinical trial.
The company reported completion of an animal safety study assessing toxicology, tumorigenicity, and biodistribution. The reported study found no treatment-related toxicity, tumor formation, or migration to distant organs or tissues.
The company began an IND-enabling animal efficacy study for its neural tissue implant. Planned assessments include motor and sensory recovery, behavioral testing, and histological analysis.
The company began engineering runs intended to validate clinical manufacturing processes under GMP conditions, including production activities for the cellular component of its implant platform.
The company was selected for the award at Advanced Therapies Week, according to the announcement.
The company reported FDA feedback supporting key elements of its proposed trial, including the patient population, open-label single-arm design, and safety assessments. The feedback was based on a limited trial synopsis and is not clearance of an IND or authorization to begin a trial.
The company reported approval to collect blood samples from patients with complete spinal cord injuries for induced pluripotent stem cell generation. The approval does not authorize implantation or initiation of a clinical trial.
The company reported completion of an animal safety study assessing toxicology, tumorigenicity, and biodistribution. The reported study found no treatment-related toxicity, tumor formation, or migration to distant organs or tissues.
The company began an IND-enabling animal efficacy study for its neural tissue implant. Planned assessments include motor and sensory recovery, behavioral testing, and histological analysis.
The company began engineering runs intended to validate clinical manufacturing processes under GMP conditions, including production activities for the cellular component of its implant platform.